Adelaide, 10 December 2008: LabTech Systems (ASX: LBT) is pleased to announce that the PREVI™ Isola, incorporating LabTech Systems’ MicroStreak® technology, has been successfully launched by bioMérieux, a world leader in in vitro diagnostics, and the first commercial sales to clinical laboratories have been made.
The PREVI™ Isola is the first instrument to incorporate the MicroStreak® technology. This automated agar plate streaker performs one of the core tasks of diagnostic microbiology, and has the capacity to offer significant time, space and cost savings to laboratory operators. In the current trend of laboratory concentration, there is strong demand for automation that can standardize processes and provide traceability, timesaving and optimized workflow, as well as improved safety. The PREVI™ Isola offers staff the opportunity to use their time in more valuable activities that relate to patient care.
The PREVI™ Isola is being marketed by LabTech Systems international partner, bioMérieux. The commercial launch is beginning in mid-sized clinical microbiology laboratories in the USA and certain Western European countries. LabTech Systems will receive royalty payments on sales of the patented disposable applicators that effect the agar plate streaking.
Lusia Guthrie, CEO and Managing Director of LabTech Systems, said, “We are delighted to see the full commercial launch of the first product using our MicroStreak® technology. We look forward to our continuing relationship with bioMérieux and hope that PREVI™ Isola, the leading automation solution available today, will become the standard in clinical microbiology.”
About LabTech Systems
LabTech Systems is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company was formed in 2004 and listed on the Australian Securities Exchange on 31 July 2006 (ASX: LBT). The current focus of the company is the commercialisation of its first product, known as MicroStreak®. In 2007, LabTech Systems signed an agreement with French diagnostics giant bioMérieux to commercialise and market this invention. MicroStreak® will comprise a central part of bioMérieux’s PREVI™ range of automated diagnostic laboratory equipment. Going forward, the Company intends to continue its track record of innovation while also fully exploiting its existing commercial relationships and intellectual property portfolio.
For more information, see www.labtechsystems.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company’s current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
